BioNTech: Advancing science to help transform cancer and ...
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases.
BioNTech - Wikipedia
BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz …
BioNTech Provides Strategic Business Update and Outlines 2026 ...
2 days ago · Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus …
BioNTech Open to Preferred Partnership as Cancer Drugs ...
19 hours ago · BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a …
BioNTech Finalizes CureVac Acquisition: A Strategic ...
4 days ago · The BioNTech-CureVac merger is a definitive moment in the history of mRNA technology, marking the transition from a fragmented field of pioneers to a consolidated …
BioNTech Provides Strategic Business Update and Outlines
2 days ago · Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus …
BioNTech completes CureVac takeover and updates articles of ...
Jan 6, 2026 · BioNTech SE is a German biotechnology company based in Mainz that focuses on the research, development, manufacture and marketing of immunological and RNA-based …